Theravance Biopharma Inc Cash Flow Conversion Efficiency
Theravance Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.06 Million) by net assets ($296.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Theravance Biopharma Inc (2011–2025)
Cash flow conversion efficiency of Theravance Biopharma Inc from 2011 to 2025. This chart illustrates how Theravance Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Theravance Biopharma Inc for real-time trading data and today's change.
Theravance Biopharma Inc Cash Flow Conversion Ratio Explained
Theravance Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Theravance Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theravance Biopharma Inc ranked by their cash flow conversion efficiency. Also see TBPH stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Asia Pacific Light Alloy Technology Co Ltd
SHE:002540
|
-0.018x |
|
Jiangxi Guotai Civilian
SHG:603977
|
-0.035x |
|
Aarti Pharmalabs Limited
NSE:AARTIPHARM
|
0.019x |
|
Whirlpool China Co Ltd
SHG:600983
|
0.057x |
|
Indus Holding AG
XETRA:INH
|
0.096x |
|
Cisen Pharmaceutical Co Ltd
SHG:603367
|
0.049x |
|
Kayne Anderson BDC, Inc.
NYSE:KBDC
|
0.037x |
|
Dios Fastigheter AB
ST:DIOS
|
0.019x |
Annual Cash Flow Conversion Efficiency for Theravance Biopharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Theravance Biopharma Inc from 2011 to 2025. Review Theravance Biopharma Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $296.72 Million | $238.54 Million | 0.804x | +1323.44% |
| 2024-12-31 | $175.54 Million | $-11.54 Million | -0.066x | +48.16% |
| 2023-12-31 | $213.00 Million | $-27.00 Million | -0.127x | +70.05% |
| 2022-12-31 | $441.80 Million | $-186.99 Million | -0.423x | -168.94% |
| 2021-12-31 | $-338.57 Million | $-207.86 Million | 0.614x | -25.53% |
| 2020-12-31 | $-303.75 Million | $-250.40 Million | 0.824x | -22.53% |
| 2019-12-31 | $-223.84 Million | $-238.20 Million | 1.064x | -51.36% |
| 2018-12-31 | $-51.59 Million | $-112.87 Million | 2.188x | +225.33% |
| 2017-12-31 | $115.18 Million | $-201.05 Million | -1.746x | -517.60% |
| 2016-12-31 | $350.23 Million | $-98.99 Million | -0.283x | +59.31% |
| 2015-12-31 | $243.06 Million | $-168.86 Million | -0.695x | -14.94% |
| 2014-12-31 | $289.79 Million | $-175.16 Million | -0.604x | -108.51% |
| 2013-12-31 | $-17.04 Million | $-120.96 Million | 7.101x | -89.81% |
| 2012-12-31 | $-1.71 Million | $-119.11 Million | 69.653x | +11648.91% |
| 2011-12-31 | $-140.72 Million | $-83.43 Million | 0.593x | -- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic n… Read more